EGFR and neoplasm: By simultaneously targeting EGFR and MET receptor pathways in platinum-based chemotherapy-resistant cancer cases, amivantamab demonstrates both direct killing of tumor cells and enhanced cytolytic susceptibility (Billowria et al., 2023).